LN-229 glioblastoma multiforme cell line expresses CD155 (PVR), a target for Natural Killer Cell-mediated immunotherapy




Journal Title

Journal ISSN

Volume Title



Purpose: Glioblastoma multiforme (GBM) is the most common form of primary brain cancer in adults. Currently, it has a dismal five-year survival rate of less than 7%. Current commonplace treatment options include surgery, chemotherapy, and radiation. In recent years, there has been a major attempt at bringing the immunotherapy revolution into the treatment pillars for GBM. Immunotherapies depend upon targeting molecular antigens that are unique to cancer cells. Our lab is currently working to identify novel antigens on GBM as future candidates for Natural Killer (NK) cell-mediated immunotherapy. In several cancers, the surface antigen known as CD155 (PVR) has been shown to be overexpressed and is important as part of a mechanism for cancer cells to evade NK cell and T cell-mediated immune responses. Typically, CD155 is not highly expressed on healthy cells, making it an attractive immunotherapy target. We set out here to investigate the expression of CD155 on LN-229 cells. Methods: We examined the expression of CD155 on the LN-229 GBM cell line using flow cytometry utilizing PE-labeled antibodies specific for CD155. Our hypothesis: LN-229 cells would show increased detection of fluorescence signal (from anti-CD155 antibodies) when compared to the fluorescence detection of negative control groups (no staining group and PE-isotype control group). Results: CD155 detected on LN-229 cells via the detection of increased fluorescence signal (versus negative controls). Conclusions: Based on our results, we concluded that CD155 is overexpressed on the LN-229 cell line and is a sufficient candidate for studying NK cell-mediated immunotherapy in in vitro contexts using LN-229 cells. Currently, we are evaluating blocking inhibitory signals to NK cells mediated through the CD155-TIGIT interaction to target GBM for NK cytotoxicity in LN-229 cells.